Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) [Hematologic Malignancy]

Conclusion LR is more active than lenalidomide alone in recurrent FL with similar toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel agents.

http://jco.ascopubs.org/cgi/content/short/33/31/3635?rss=1

Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Leonard, Jung, Johnson, Pitcher, Bartlett, Blum, Czuczman, Giguere, Cheson Tags: Biologic Therapy Hematologic Malignancy Source Type: research